Immunophotonics
↗Saint Louis, Missouri, USA
Immunophotonics is a privately held, clinical-stage biotechnology company pioneering the field of Interventional Immuno-Oncology®, a transformational approach to treating solid tumors. The company has developed a proprietary technology platform centered on IP-001, an immune-modulating synthetic biopolymer designed to enhance tumor-specific immune responses when combined with thermal ablation procedures. The platform works by liberating tumor antigens during ablation, enhancing immune system interactions with these antigens, and promoting long-term protective immunity against cancer. Immunophotonics operates with subsidiaries in Bern, Switzerland and Tianjin, China, and is advancing multiple clinical development programs targeting solid-tumor cancers across multiple indications.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology Biotech - Immuno-Oncology
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
FUNDING
Stage:Series B+
Total Raised:$93.9M
Investors:Zubizoom Investments LLC, ROVAQ Ventures LLC, Johnson & Johnson Innovation, Horizen Capital, SeedFolio, iSelect Fund, Immune LLC
PIPELINE
Stage:Phase 2/3
Lead Drug Stage:Phase 2/3
Modalities:Synthetic biopolymer, Immune-modulating agent, Intratumoral injection
Active Trials:3
Trial Phases:Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Bern, Switzerland operations, Tianjin, China operations
Key Partnerships:Swiss Cancer Institute - SAKK 66/17 trial collaboration (completed), Clinical Laserthermia Systems - thermal ablation collaboration, CIRSE (Cardiovascular and Interventional Radiological Society of Europe) - INJECTABL-3 trial partner, Next Research - Clinical trial management (INJECTABL-3)
COMPETITION
Position:Emerging
Competitors:Intezyne Technologies, Step Pharma, CNS Pharmaceuticals, Anokion
LEADERSHIP
Key Executives:
Miguel Zubizarreta - CEO
Dr. Robert Arch - President
Dr. Tomas Hode - Chief Innovation Officer & Co-Founder
Lu Alleruzzo - Director & Co-Founder
Dr. Beatty - VP of Regulatory & Clinical Affairs
Dr. Lam - SVP of Science and Research
Kelly Porterfield - Director of Clinical Operations
Scientific Founders:Dr. Tomas Hode, Lu Alleruzzo, Dr. Chen (co-inventor of inCVAX/IP-001)
Board Members:Richard M. Levenson, M.D. (added November 2025)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Immunophotonics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Immunophotonics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.